Biochemistry Quiz: Receptors And Ligand Binding Affinity Kd

What this quiz covers

This quiz focuses on Receptors And Ligand Binding Affinity Kd, giving you a quick way to practice the rules, question types, and explanations that matter most for Biochemistry.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. 15 nM
2. 30 nM
3. 60 nM (correct answer)
4. 120 nM

Explanation: First, calculate the fractional saturation (θ) for Ligand B at 240 nM: θ = [L] / ([L] + Kd) = 240 / (240 + 120) = 240 / 360 = 2/3. Next, use this θ value to find the required concentration of Ligand A. For Ligand A, the equation is 2/3 = [A] / ([A] + 30 nM). Rearranging gives 2 * ([A] + 30) = 3 * [A], which simplifies to 2[A] + 60 = 3[A]. Solving for [A] gives [A] = 60 nM.

Question 2

1. Receptor A has a higher affinity for the hormone and requires a lower hormone concentration to achieve 50% saturation compared to Receptor B. (correct answer)
2. Receptor B has a higher affinity for the hormone and requires a lower hormone concentration to achieve 50% saturation compared to Receptor A.
3. Receptor A has a lower affinity for the hormone but will bind a greater total amount of hormone at saturation than Receptor B.
4. Both receptors have the same affinity for the hormone, but Receptor A binds at a faster rate, which is reflected in its lower Kd value.

Explanation: The dissociation constant (Kd) is inversely proportional to binding affinity. A lower Kd indicates a higher affinity. Therefore, Receptor A (Kd = 15 nM) has a higher affinity than Receptor B (Kd = 150 nM). By definition, the Kd is the ligand concentration required to achieve 50% saturation of the receptors. Thus, Receptor A will be half-saturated at a lower hormone concentration (15 nM) than Receptor B (150 nM).

Question 3

1. It decreases the apparent Kd for the neurotransmitter, making it appear to bind more tightly.
2. It increases the apparent Kd for the neurotransmitter but does not alter the maximal binding (Bmax). (correct answer)
3. It decreases the maximal binding (Bmax) of the neurotransmitter without affecting the Kd.
4. It forms a covalent bond with the receptor, permanently reducing both the Kd and Bmax.

Explanation: A competitive antagonist competes with the natural ligand for the same binding site. This competition means that a higher concentration of the natural ligand is needed to achieve the same level of receptor occupancy. This is reflected as an increase in the apparent dissociation constant (Kd). Because the antagonist is reversible, its effect can be overcome by a sufficiently high concentration of the natural ligand, so the maximal number of binding sites (Bmax) remains unchanged.

Question 4

1. 0.25
2. 0.33
3. 0.50
4. 0.75 (correct answer)

Explanation: Fractional occupancy (θ) is calculated using the formula θ = [L] / ([L] + Kd), where [L] is the ligand concentration and Kd is the dissociation constant. Plugging in the values: θ = 120 µM / (120 µM + 40 µM) = 120 / 160 = 12 / 16 = 3 / 4 = 0.75.

Question 5

1. Partitioning of a hydrophobic ligand into a lipid bilayer, which follows a linear relationship.
2. Low-affinity, non-specific binding of a charged ligand to many sites on a protein surface.
3. High-affinity binding of a ligand to a specific, finite population of receptor proteins. (correct answer)
4. The binding of a ligand at concentrations that are more than 100-fold below its Kd value.

Explanation: The defining characteristic of specific binding to a finite number of receptors is saturability. As the ligand concentration increases, the binding sites become occupied, and eventually, the amount of bound ligand plateaus at a maximum value (Bmax). The observation of a linear relationship without saturation is characteristic of non-specific binding or partitioning, not high-affinity, specific binding to a limited number of sites.

Question 6

1. At 0.01 nM, where the system is most sensitive to the initial presence of the hormone.
2. At 1.0 nM, where the binding curve is steepest and the receptor is half-saturated. (correct answer)
3. At 100 nM, where the receptor is nearly saturated and the response is maximal.
4. At any concentration, as the change in occupancy is linearly proportional to the change in ligand concentration.

Explanation: The largest change in receptor occupancy for a given change in ligand concentration occurs when the ligand concentration is equal to the Kd. At this point, the binding curve (plotting fractional occupancy vs. log[ligand]) is at its steepest inflection point. At concentrations far below Kd (like 0.01 nM), there is little binding. At concentrations far above Kd (like 100 nM), the receptor is nearly saturated, and further increases in ligand concentration cause very small changes in occupancy.

Question 7

1. 20 nM
2. 25 nM
3. 80 nM (correct answer)
4. 100 nM

Explanation: The formula for fractional occupancy (θ) is θ = [L] / ([L] + Kd). We are given θ = 0.80 and Kd = 20 nM, and we need to solve for [L]. The equation becomes 0.80 = [L] / ([L] + 20 nM). Rearranging gives 0.80 * ([L] + 20) = [L], which simplifies to 0.80[L] + 16 = [L]. Subtracting 0.80[L] from both sides gives 16 = 0.20[L]. Solving for [L] yields [L] = 16 / 0.20 = 80 nM.

Question 8

1. Drug Y has the highest affinity for the target protein because it has the lowest Ka value.
2. Drug Z has the highest affinity for the target protein because it has the largest Ka value. (correct answer)
3. Drug X has the highest affinity because its Ka value is an intermediate between Y and Z.
4. All three drugs have approximately the same affinity, as the Ka values are all within two orders of magnitude.

Explanation: The association constant (Ka) is directly proportional to binding affinity; a larger Ka signifies stronger binding. Comparing the values, Drug Z has the largest Ka (5.0 x 10⁸ M⁻¹), followed by Drug X (2.5 x 10⁸ M⁻¹), and then Drug Y (1.0 x 10⁷ M⁻¹). Therefore, Drug Z has the highest affinity.

Question 9

1. The individual will perceive the odor as being much stronger than normal at low concentrations.
2. The individual will require a much higher concentration of the odorant to detect the smell. (correct answer)
3. The receptor will become constitutively active, signaling the presence of the odorant at all times.
4. The binding of the odorant will become effectively irreversible, causing prolonged signal activation.

Explanation: An increase in the Kd signifies a decrease in binding affinity. The mutant receptor (Kd = 800 µM) binds the odorant much more weakly than the wild-type receptor (Kd = 10 µM). Consequently, a significantly higher concentration of the odorant molecule is required to achieve the same level of receptor occupancy and trigger a neural signal, making the individual less sensitive to the smell.

Question 10

1. A high k_on and a high k_off, to ensure rapid binding and release from the target.
2. A low k_on and a high k_off, to minimize binding and maximize dissociation.
3. A low k_off and a high k_on, to promote rapid binding and very slow dissociation. (correct answer)
4. A low k_on and a low k_off, to ensure slow binding followed by slow dissociation.

Explanation: High potency is associated with high affinity, which corresponds to a low Kd. A low Kd is achieved by having a low k_off (slow dissociation) and/or a high k_on (fast association). A long duration of action (long residence time) is directly related to a very slow dissociation rate, meaning a very low k_off. Therefore, the ideal combination for a potent, long-acting drug is a high k_on and a very low k_off.

Question 11

1. 0.20
2. 0.50
3. 0.80 (correct answer)
4. 0.95

Explanation: First, ensure the concentrations are in the same units. The ligand concentration is 0.20 µM, which is equal to 200 nM. The Kd is 50 nM. Now, use the fractional saturation formula: θ = [L] / ([L] + Kd). Plugging in the values: θ = 200 nM / (200 nM + 50 nM) = 200 / 250 = 20 / 25 = 4 / 5 = 0.80.

Question 12

1. The PAM would increase the Kd of the natural ligand, signifying weaker binding.
2. The PAM would convert the reversible binding of the ligand into an irreversible covalent linkage.
3. The PAM would have no effect on the Kd but would increase the maximum number of binding sites (Bmax).
4. The PAM would decrease the Kd of the natural ligand, signifying tighter binding. (correct answer)

Explanation: When you encounter questions about allosteric modulation, focus on how these compounds change receptor properties by binding at sites separate from the main ligand binding site. The key insight is understanding what happens to binding affinity when receptors undergo conformational changes. A positive allosteric modulator (PAM) enhances receptor function by increasing the receptor's affinity for its natural ligand. Since the dissociation constant (Kd) represents the concentration of ligand needed to occupy half the receptors at equilibrium, a lower Kd value indicates stronger binding affinity. When the PAM induces a conformational change that increases affinity, it decreases the Kd value, making the natural ligand bind more tightly to the receptor. Looking at the incorrect options: Choice A is backwards—increased affinity means decreased Kd, not increased. Choice B misrepresents the mechanism entirely; PAMs don't convert reversible binding into irreversible covalent bonds—they simply stabilize the ligand-receptor complex through conformational changes. Choice C confuses affinity changes with capacity changes; while some modulators might affect receptor expression or availability (Bmax), a PAM specifically increases binding affinity, which directly affects Kd. Remember this pattern: positive allosteric modulators always improve binding characteristics. "Positive" means enhanced function, and enhanced binding affinity always corresponds to a lower Kd value. This relationship—better binding equals lower Kd—applies across all receptor-ligand interactions, whether influenced by allosteric modulators or not.

Question 13

1. Benlor is the superior drug because its higher Kd ensures it can be more easily cleared from the body, preventing toxicity.
2. The difference in Kd indicates that Inhixa binds more slowly but for a longer duration, while Benlor binds rapidly but for a shorter duration.
3. Both drugs will be equally potent in a clinical setting, as in vitro Kd values rarely correlate with in vivo efficacy or required dosage.
4. Inhixa is expected to be a more potent inhibitor, meaning a substantially lower dose should be required to produce the same level of enzyme inhibition. (correct answer)

Explanation: When you encounter competitive inhibition problems, focus on what the dissociation constant (Kd) reveals about binding affinity. The Kd represents the concentration of inhibitor needed to occupy 50% of the enzyme's active sites - lower Kd means stronger binding and higher potency. Inhixa's Kd of 4 nM versus Benlor's 400 nM means Inhixa binds 100-fold more tightly to the enzyme. This translates directly to therapeutic advantage: you need far less Inhixa to achieve the same level of enzyme inhibition. If you needed 400 nM of Benlor in tissue to block half the enzyme molecules, you'd only need 4 nM of Inhixa for identical inhibition. This makes answer D correct - Inhixa's superior binding affinity means substantially lower doses are required. Answer A incorrectly suggests higher Kd is beneficial for clearance, but drug clearance depends on metabolism and excretion pathways, not target binding affinity. Answer B confuses Kd with kinetic parameters - Kd reflects equilibrium binding strength, not the speed of association or dissociation. Answer C dismisses the clinical relevance of Kd values, but binding affinity is fundamental to drug potency and directly influences dosing requirements, especially when other factors like bioavailability are comparable. Remember: lower Kd = higher affinity = greater potency = lower required dose. This relationship is crucial for understanding structure-activity relationships and drug optimization in medicinal chemistry. Always convert Kd comparisons into practical dosing implications.

Question 14

1. The apparent Kd at pH 7.0 would be higher than at pH 5.0, because at pH 7.0 a smaller fraction of the ligand is in the required protonated state. (correct answer)
2. The apparent Kd at pH 7.0 would be lower than at pH 5.0, because the higher pH more closely resembles physiological conditions for binding.
3. The apparent Kd would be identical in both conditions because pH only affects the binding rate, not the equilibrium affinity.
4. The apparent Kd at pH 7.0 would be higher than at pH 5.0, because the receptor itself is denatured at the more acidic pH of 5.0.

Explanation: The ligand's amine group (pKa 8.0) must be protonated for binding. At pH 7.0 (one pH unit below the pKa), the ligand is mostly protonated, but a significant fraction (about 10%) is deprotonated. At pH 5.0 (three pH units below the pKa), the ligand is almost fully protonated (>99.9%). Since the concentration of the active, protonated form is lower at pH 7.0 than at pH 5.0, a higher total ligand concentration is needed to achieve the same level of binding. This results in a higher apparent Kd at pH 7.0 compared to the intrinsic Kd observed at a more optimal pH like 5.0.

Question 15

1. $K_d = 5$ nM, indicating high affinity binding (correct answer)
2. $K_d = 10$ nM, indicating moderate affinity binding
3. $K_d = 2.5$ nM, indicating very high affinity binding
4. $K_d = 15$ nM, indicating low affinity binding

Explanation: At 50% receptor occupancy, the ligand concentration equals the Kd value. Since 50% occupancy occurs at 5 nM hormone, Kd = 5 nM. The total receptor concentration (10 nM) is irrelevant to the Kd calculation. A Kd of 5 nM indicates high affinity (low nanomolar range). Choice B incorrectly uses total receptor concentration. Choice C miscalculates by dividing the ligand concentration by 2. Choice D adds ligand and receptor concentrations incorrectly.

Question 16

1. $K_d$ increases 100-fold; physiological response requires 100-fold higher ligand concentrations for equivalent activation (correct answer)
2. $K_d$ decreases 100-fold; physiological response shows enhanced sensitivity to ligand
3. $K_d$ increases 10-fold; physiological response shows moderate reduction in ligand sensitivity
4. $K_d$ remains unchanged; physiological response shows normal ligand sensitivity due to intact signaling

Explanation: If 100-fold higher ligand concentration is needed for the same occupancy, the Kd has increased 100-fold (lower affinity). Since physiological responses depend on receptor occupancy, and occupancy now requires 100-fold higher ligand concentrations, the dose-response curve shifts right by 100-fold. Choice B has the wrong direction for Kd change. Choice C underestimates the magnitude. Choice D incorrectly assumes that normal signaling when occupied compensates for reduced binding affinity.

Question 17

1. The mutant receptor has a 50-fold reduction in ligand binding affinity that wasn't detected in the binding assay
2. The mutant receptor undergoes rapid degradation after ligand binding, requiring higher concentrations for sustained signaling
3. The cell line expresses 50-fold fewer mutant receptors than wild-type receptors per cell
4. The mutant receptor binds ligand normally but has severely impaired coupling to downstream signaling pathways (correct answer)

Explanation: When you encounter receptor pharmacology questions, focus on the distinction between binding affinity (how well a ligand sticks to its receptor) and functional response (how effectively that binding translates into cellular signaling). These are separate, measurable properties that can be disrupted independently. Here, the mutant receptor binds ligand with normal affinity ($K_d = 5$ nM), meaning the ligand-receptor interaction itself is intact. However, the biological response requires 50-fold higher concentrations ($EC_{50} = 250$ nM vs. 5 nM), indicating a severe defect in signal transduction. This pattern points to D - the receptor binds normally but cannot effectively couple to downstream signaling pathways, likely due to mutations affecting intracellular domains or conformational changes needed for signaling. A is incorrect because the binding assay directly measured normal affinity ($K_d = 5$ nM). Binding assays are specifically designed to detect affinity changes. B fails because rapid receptor degradation would typically affect both binding measurements and require even higher sustained concentrations, plus degradation usually occurs over minutes to hours, not the timeframe of most functional assays. C is wrong because reduced receptor expression would shift both the binding curve and functional response proportionally - you'd see changes in maximum binding capacity, not just functional response. Study tip: Remember that receptor function involves two distinct steps: ligand binding and signal transduction. When you see normal binding but impaired function, think "coupling defect" - the receptor can still recognize its ligand but can't properly activate downstream signaling machinery.

Question 18

1. ATP acts as a competitive inhibitor, reducing insulin's apparent affinity for the receptor
2. ATP binding to the receptor induces a conformational change that increases insulin binding affinity (correct answer)
3. ATP directly binds to insulin, forming a complex with higher receptor affinity
4. ATP increases receptor expression, leading to more available binding sites for insulin

Explanation: A decrease in Kd indicates increased affinity (tighter binding), while unchanged maximum binding means the same number of receptors are present. This suggests ATP binding to the receptor causes an allosteric conformational change that enhances insulin binding affinity. Choice A incorrectly describes competitive inhibition, which would increase Kd. Choice C is unlikely since ATP and insulin have very different structures. Choice D is wrong because maximum binding capacity remained unchanged, indicating no change in receptor number.

Question 19

1. $K_{d1} = 1$ μM and $K_{d2} = 1$ μM, indicating identical binding affinities
2. $K_{d1} = 1$ nM and $K_{d2} = 1$ μM, indicating the fast phase has higher affinity
3. $K_{d1} = 1$ μM and $K_{d2} = 1$ nM, indicating the slow phase has higher affinity (correct answer)
4. $K_{d1} = 10$ μM and $K_{d2} = 0.1$ nM, indicating a 100,000-fold difference in affinity

Explanation: When you encounter biphasic binding kinetics, you're dealing with a ligand that can bind to its receptor in two distinct ways, each with different kinetic properties. The key is calculating the equilibrium dissociation constant ($K_d$) for each phase using the relationship $K_d = k_{off}/k_{on}$. For the fast phase: $K_{d1} = k_{off1}/k_{on1} = 10^{-2}/10^7 = 10^{-9}$ M = 1 nM For the slow phase: $K_{d2} = k_{off2}/k_{on2} = 10^{-4}/10^5 = 10^{-6}$ M = 1 μM Since $K_d$ represents the concentration at which half the receptors are bound, a smaller $K_d$ indicates higher affinity. The fast phase (1 nM) has 1000-fold higher affinity than the slow phase (1 μM). Answer A incorrectly calculates both $K_d$ values and misses that they represent different affinities. Answer B reverses the $K_d$ values, incorrectly stating the fast phase has higher affinity when it actually has the lower $K_d$ (higher affinity). Answer D contains calculation errors, dramatically overestimating both the $K_d$ values and the fold-difference. Answer C correctly identifies $K_{d1} = 1$ nM and $K_{d2} = 1$ μM, properly recognizing that the slow phase has higher affinity because it has the smaller $K_d$ value. Study tip: Always remember that $K_d = k_{off}/k_{on}$ and that smaller $K_d$ values mean tighter binding (higher affinity). In biphasic kinetics, don't assume the "fast" phase necessarily means higher affinity—calculate the $K_d$ values to determine which phase binds more tightly.